FlexShares Quality Dividend Index Fund (QDF): outlook, holdings and fees
FlexShares Quality Dividend Index Fund (QDF) is an exchange-traded fund and is managed by Northern Trust. The expense ratio is 0.36% and the yield is 1.53%. The ten largest holdings are 39% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on QDF
| Last price | $91.02 (+0.6%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 57% |
| Likely 1-month range (50%) | $89.65 – $93.39 |
| Normal 1-day range (±1σ) | ±0.7% |
| Distribution yield | 1.53% · quarterly |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
QDF fund facts
| Issuer | Northern Trust |
|---|---|
| Theme | Dividend stocks |
| Assets under management | $2.2B |
| Expense ratio | 0.36% |
| Number of holdings | 49 |
| Portfolio turnover | 53% |
| Inception | Dec 14, 2012 |
| Exchange | NYSE |
The underlying index is designed to reflect the performance of a selection of companies that, in aggregate, provide exposure to a high-quality income-oriented universe of long-only U.S. equity securities, with an emphasis on long-term capital growth and a targeted overall beta that is similar to that of the Northern Trust 1250 Index (the "parent index"), a float-adjusted market-capitalization weighted index of U.S. domiciled large- and mid-capitalization companies.
QDF top holdings
| Holding | Sector | Weight |
|---|---|---|
| Apple Inc. AAPL | Technology | 9.42% |
| NVIDIA Corporation NVDA | Technology | 7.65% |
| Microsoft Corporation MSFT | Technology | 4.38% |
| Johnson & Johnson JNJ | Healthcare | 2.80% |
| Lam Research Corp LRCX | Technology | 2.83% |
| Broadcom Inc AVGO | Technology | 2.57% |
| JPMorgan Chase & Co JPM | Financial Services | 2.36% |
| Alphabet Inc Class A GOOGL | Communication Services | 2.45% |
| General Electric Company GCP | Other | 2.19% |
| Philip Morris International Inc PM | Consumer Defensive | 1.96% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
QDF sector breakdown
| Sector | Weight |
|---|---|
| Technology | 36.9% |
| Financial Services | 12.8% |
| Industrials | 9.4% |
| Healthcare | 8.7% |
| Communication Services | 8.1% |
| Consumer Cyclicals | 6.9% |
| Consumer Defensive | 5.3% |
| Real Estate | 4.8% |
| Energy | 3.1% |
| Utilities | 2.7% |
| Basic Materials | 1.3% |
By region: North America 99.3%, Europe Developed 0.5%, Asia Emerging 0.2%.
QDF returns and risk
| Year to date | +14.6% |
|---|---|
| 1 year | +16.9% |
| 3 years (annualised) | +19.3% |
| 5 years (annualised) | +12.8% |
| 10 years (annualised) | +11.9% |
| Volatility (3 years) | 11.1% |
| Sharpe ratio (3 years) | 1.23 |
Past returns do not guarantee future results.
QDF: frequently asked questions
What does QDF invest in?
FlexShares Quality Dividend Index Fund invests in a portfolio of securities. Its largest holdings are Apple Inc. (9.4%), NVIDIA Corporation (7.6%), Microsoft Corporation (4.4%), Johnson & Johnson (2.8%), Lam Research Corp (2.8%).
What is the QDF expense ratio?
0.36% a year: about $36.00 for every $10,000 invested.
What is the QDF dividend yield?
1.53%, paid quarterly. ATLAS does not hold the exact distribution dates for ETFs.
Will QDF go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 57%, with a likely range (50%) of $89.65 to $93.39 from $91.02 today. It is a probability, not a prediction.
How has QDF performed?
Year to date +14.6%, one year +16.9%, three years +19.3% a year, five years +12.8% a year. Past returns do not guarantee future results.
Similar ETFs: Dividend stocks
- Vanguard Dividend Appreciation ETF (VIG)
- Vanguard High Dividend Yield ETF (VYM)
- iShares Core Dividend Growth ETF (DGRO)
- Capital Group Dividend Value ETF (CGDV)
- First Trust Rising Dividend Achievers ETF (RDVY)
- iShares Select Dividend ETF (DVY)
- State Street SPDR S&P Dividend ETF (SDY)
- iShares Core High Dividend ETF (HDV)
Educational information, not investment advice. Disclaimer